Our passion for making a difference unites us.
Amicus Therapeutics is a global, patient-dedicated biotech focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic
Living with CDKL5 Deficiency Disorder
We are a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare diseases.
Extraordinary Patient Focus
At Amicus, patient-centricity is in our DNA. See how our commitment to patients goes further than just our medicines and expands out to the rare disease community at large.
News & Announcements
March 19, 2020
First and foremost, your safety and welfare and that of your families always has been and continues to be our number one priority. This is especially true in view of the global COVID-19 outbreak. Amicus remains committed to open and frequent communications to address any questions. We are in this fight together. We will maintain consistent monitoring of this unprecedented situation, provide updates of any changes and remain available to you.
Given current information, we have a high degree of confidence that all Amicus-sponsored clinical studies across all programs are continuing as planned, and that supply of Galafold® will continue uninterrupted.
Clinical study participants and their family members can bring specific questions to their respective study site staff, as well as to Amicus Patient & Professional Advocacy at email@example.com or 1-866-9-AMICUS (926-4287) toll-free in the US and Canada or +1.609-662.2000.
For those prescribed Galafold® in the US, you can call Amicus assist toll free at 1-833-AMICUS-A (1-833-264-2872), or reach out to your healthcare provider. >